DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Epidemiology and Control of Mansonella Perstans Infection in Uganda

Information source: DBL -Institute for Health Research and Development
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mansonelliasis; Pruritus; Lymphoedema; Abdominal Pains

Intervention: ivermectin and albendazole (Drug)

Phase: N/A

Status: Completed

Sponsored by: DBL -Institute for Health Research and Development

Official(s) and/or principal investigator(s):
Asanta M Asio, Msc, Principal Investigator, Affiliation: Vector control Division, Kampala, Uganda


Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.

Clinical Details

Official title: Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

microfilariae periodicity patterns

epidemiology of M. perstans at community level

clinical spectre among infected

reduction in microfilaraemia

Secondary outcome: treatment effect on clinical manifestations

Detailed description: Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control Specific objectives: 1. To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans 2. To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity 3. To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.


Minimum age: 5 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Individuals >= 5 years with or without M. perstans infection

Exclusion Criteria:

- Individuals < 5 years

- Pregnant women

Locations and Contacts

Luwero, Luwero and Mukono, Luwero and Mukono Districts, Uganda
Additional Information

Starting date: November 2005
Last updated: April 19, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017